Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Proctos Kliniek, Bilthoven, The Netherlands.
Colorectal Dis. 2021 Aug;23(8):2119-2126. doi: 10.1111/codi.15696. Epub 2021 May 16.
Injection of Permacol collagen paste can be used as a sphincter-sparing treatment for perianal fistulas. In a tertiary referral population we aimed to evaluate the efficacy of Permacol injection and the clinical and fistula-related factors associated with recurrence.
This was a retrospective analysis of consecutive patients with perianal fistulas treated with Permacol injection at a specialist centre between June 2015 and April 2019. Endoanal ultrasonography was systematically reanalysed, blinded to treatment outcome. Rectovaginal, anovaginal and Crohn's disease fistulas were excluded. Healed fistulas were defined as absent anal symptoms and a closed external opening on physical examination at a minimum follow-up of 6 months. Regression analyses were performed to identify factors associated with unhealed fistulas.
A total of 90 patients (51 men; median age 45 years) were analysed. Seventy-two (80.0%) patients had complex perianal fistulas (greater than one-third sphincter involvement or multiple tracts). After a single Permacol injection, fistulas were healed in 20 (22.2%) patients at 3 months follow-up and in 18 (20.0%) patients at a median follow-up of 30 months (interquartile range 17-37). Eight (11.1%) patients with unhealed fistulas had significant improvement in their symptoms. Complex fistulas were significantly associated with unhealed status [OR 3.53 (95% CI 1.12-11.09); p = 0.031]. Twenty patients underwent subsequent Permacol injections, which were successful in six (30.0%) patients after one (n = 3) or two (n = 3) additional injections.
This largest study to date in patients with mainly complex perianal fistulas, demonstrated that the efficacy of a single Permacol injection was only 20%. Complex fistulas were associated with a poor outcome.
Permacol 胶原膏注射可作为肛门括约肌保留治疗肛周瘘的方法。在三级转诊人群中,我们旨在评估 Permacol 注射的疗效,以及与复发相关的临床和瘘管相关因素。
这是一项对 2015 年 6 月至 2019 年 4 月在一家专科中心接受 Permacol 注射治疗的肛周瘘患者进行的连续病例回顾性分析。对所有患者均行直肠腔内超声检查,分析时不考虑治疗结果。排除直肠阴道瘘、阴道肛门瘘和克罗恩病瘘。愈合的瘘管定义为在至少 6 个月的随访中,肛门无明显症状,体格检查时外口封闭。采用回归分析确定与未愈合瘘管相关的因素。
共分析了 90 例患者(51 例男性;中位年龄 45 岁)。72 例(80.0%)患者存在复杂性肛周瘘(三分之一以上括约肌受累或存在多个瘘管)。单次 Permacol 注射后,3 个月时,20 例(22.2%)患者瘘管愈合,30 个月时(17-37 个月)18 例(20.0%)患者瘘管愈合。8 例(11.1%)未愈合瘘管患者症状明显改善。复杂瘘管与未愈合状态显著相关[比值比 3.53(95%置信区间 1.12-11.09);p=0.031]。20 例患者随后接受了 Permacol 注射治疗,2 次或 3 次注射后,6 例(30.0%)患者有效。
这是目前为止针对主要为复杂性肛周瘘患者的最大研究,表明单次 Permacol 注射的疗效仅为 20%。复杂瘘管与不良结局相关。